Pharmacodynamic Effects and Predictive Biomarkers of JAK/STAT Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial

Trial Profile

Pharmacodynamic Effects and Predictive Biomarkers of JAK/STAT Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial

Withdrawn prior to enrolment
Phase of Trial: Phase 0

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Head and neck cancer
  • Focus Pharmacodynamics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Planned initiation date changed from 1 Jan 2016 to 1 Jan 2017.
    • 06 Jun 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top